Pharmacokinetics of Midazolam and Ketamine in Critically Ill Adults on Extracorporeal Membrane Oxygenation (ECMO) Therapy

Julian Tanjuakio  
*Thomas Jefferson University*

Edwin Lam  
*Thomas Jefferson University*

Walter K. Kraft  
*Thomas Jefferson University*

Hitoshi Hirose  
*Thomas Jefferson University*

Nicholas C. Cavarocchi  
*Thomas Jefferson University*

Follow this and additional works at: [https://jdc.jefferson.edu/si_ctr_2021_phase1](https://jdc.jefferson.edu/si_ctr_2021_phase1)

Let us know how access to this document benefits you

**Recommended Citation**

Tanjuakio, Julian; Lam, Edwin; Kraft, Walter; Hirose, Hitoshi; and Cavarocchi, Nicholas, "Pharmacokinetics of Midazolam and Ketamine in Critically Ill Adults on Extracorporeal Membrane Oxygenation (ECMO) Therapy" (2019). SKMC JeffMD Scholarly Inquiry, Phase 1, Project 1.

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Pharmacokinetics of midazolam and ketamine in critically ill adults on Extracorporeal Membrane Oxygenation (ECMO) therapy

Introduction:
Extracorporeal Membrane Oxygenation (ECMO) is a form of life support for temporary mechanical cardiopulmonary support. Critically ill adults receiving ECMO support are often sedated using ketamine and benzodiazepines. Previous studies have showed altered connects of benzodiazepines and ketamine in ECMO patients compared to non-ECMO patients. However, no studies have shown prospective data regarding the pharmacokinetics of these drugs in vivo.

Objective:
The primary purpose of this study is to characterize the pharmacokinetic parameters of Ketamine and Midazolam in adult patients on ECMO. As a secondary objective, we will develop a pharmacokinetic model of these drugs using various clinical endpoints.

Methods:
Blood samples from adult patients on ECMO were taken in regular intervals over the duration of the ketamine or midazolam infusion. Quantification in plasma is preformed through an assay developed using LC-MS/MS. Clinically relevant data for each patient including demographics, ICU diagnosis, ECMO parameters, vitals, serum chemistry, and details of ICU stay were collected.

Results:
Currently 10 patients have been enrolled in the study and concentration data has been analyzed. Results have shown a pattern of discrepancy between pre-oxygenator concentration and post
oxygenator concentrations. These results are consistent with the hypothesis that drug is begin sequestered within the ECMO circuit. Further analysis correlating patient clinical data to concentration data will be used to develop a pharmacokinetic model for adult patients receiving ECMO.

**Discussion:**

Preliminary results show that there are altered kinetics of both ketamine and midazolam in adult patient on ECMO either due to the critically ill state of the patient or the ECMO circuit itself.